Targeting PIK3CA signaling to treat pancreatic cancer
PIK3CA signaling and pancreatic cancer
This study is looking at how to better target a specific pathway in pancreatic cancer to help improve treatment options, especially for patients who may not be responding well to current therapies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-10884910 on NIH RePORTER |
What this research studies
This research investigates how to effectively target PIK3CA signaling pathways to improve treatment outcomes for pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form of cancer. The study aims to understand the role of PIK3CA in tumor growth and immune evasion, utilizing animal models to explore genetic modifications and drug interventions. By examining how PIK3CA interacts with oncogenic KRAS mutations, the research seeks to identify new therapeutic strategies that could enhance the effectiveness of existing treatments, including immunotherapy. Patients may benefit from insights gained into how to overcome resistance to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
Not a fit: Patients with other types of cancer or those without KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Lin, Richard Z — State University New York Stony Brook
- Study coordinator: Lin, Richard Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.